160 related articles for article (PubMed ID: 22416383)
21. Concurrent primary angiosarcoma and invasive ductal carcinoma in the same breast.
Ni Y; Xie X; Bu H; Zhang Z; Wei B; Yin L; Chen M; Chen H; Zhang H
J Clin Pathol; 2013 Mar; 66(3):263-4. PubMed ID: 23172554
[No Abstract] [Full Text] [Related]
22. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
23. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
24. The precarious path to diagnostic accuracy: the Ontario hormone receptor guideline.
Hughes-Davies L
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):682-3. PubMed ID: 23031346
[No Abstract] [Full Text] [Related]
25. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
26. Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer.
Kuo SH; Chen CL; Huang CS; Cheng AL
Anticancer Res; 2000; 20(3B):2219-22. PubMed ID: 10928181
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
Wang YJ; Wang N; Wang B; Qin WX; Xue CY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
[TBL] [Abstract][Full Text] [Related]
28. Isolated Retinal Metastasis From Breast Cancer.
Correa de Mello P; Brasil OFM
Retina; 2017 Nov; 37(11):e125-e127. PubMed ID: 28991862
[No Abstract] [Full Text] [Related]
29. [Ductal carcinoma in situ of the breast].
Rueda Domínguez A; Alonso Muñoz MC; Gómez Gómez A; Ojeda González B
Med Clin (Barc); 1993 Oct; 101(14):548-56. PubMed ID: 8231402
[No Abstract] [Full Text] [Related]
30. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
31. An unusual case of metaplastic breast carcinoma following neoadjuvant chemotherapy.
Bigotti G; Di Filippo S; Di Filippo F; Perri P; Coli A
Pathol Int; 2012 Jan; 62(1):72-4. PubMed ID: 22192809
[No Abstract] [Full Text] [Related]
32. Hormone receptors in breast carcinomas.
Mandal AK
Indian J Pathol Microbiol; 1995 Jan; 38(1):109-18. PubMed ID: 8919478
[No Abstract] [Full Text] [Related]
33. [Effect of the proliferation rate on the course of node negative breast carcinoma].
Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
[TBL] [Abstract][Full Text] [Related]
34. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
De Maeyer L; Van Limbergen E; De Nys K; Moerman P; Pochet N; Hendrickx W; Wildiers H; Paridaens R; Smeets A; Christiaens MR; Vergote I; Leunen K; Amant F; Neven P
J Clin Oncol; 2008 Jan; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
[No Abstract] [Full Text] [Related]
35. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer.
Climent J; Martinez-Climent JA; Blesa D; Garcia-Barchino MJ; Saez R; Sánchez-Izquierdo D; Azagra P; Lluch A; Garcia-Conde J
Clin Cancer Res; 2002 Dec; 8(12):3863-9. PubMed ID: 12473601
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
38. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
39. Common questions about ductal carcinoma in situ.
Dell DD
Am J Nurs; 1997 May; 97(5):61-3, 65-6. PubMed ID: 9155799
[No Abstract] [Full Text] [Related]
40. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
